Tweet

Novatek International is pleased to announce that Agensys, Inc., an affiliate of Astellas Pharma Inc. has chosen Novatek’s microbiology environmental monitoring software program, Nova-EM from the Novatek LIMS suite of products for automating and managing their environmental monitoring and stability studies at their facility in California USA. Novatek differentiates itself by offering process-based off the shelf software solutions that meet at least 95% of user requirements readily thus providing a shorter implementation and deployment time allowing clients to go-live sooner. With the largest group of environmental monitoring users in the world Nova-EM is a conglomerate of hundreds of user requirements and incorporates the in-depth knowledge of expert microbiologists and environmental monitoring specialists. Thus Novatek was able to easily map Agensys’ standard operating procedures to Novatek's environmental monitoring software.

Novatek International is well known for excellence in project management recognizing that software solutions are only a part of the puzzle. Novatek's project managers are proficient conduits between the application and the client's process allowing for a smooth transition and a full actualization of the product. This makes system setup faster and training on the software more readily understood.

Novatek International is pleased to welcome Agensys, Inc., an affiliate of Astellas Pharma Inc. to the ranks of other prestigious clients such as, Endo Pharmaceuticals, Pfizer, Medtronic, Fresenius, Merck & Co., Inc., Lonza, Intercell, Novartis, DSM among many more, in the four corners of the world.

Novatek's microbiology environmental monitoring software is flexible, user friendly and can handle your environmental monitoring needs out of the box. Our services are second to none and our implementation and validation timelines easily beat the industry expectations every time. We invite you to evaluate our applications for yourself and find out why Novatek's environmental monitoring LIMS has been the industry standard for the last 6 years in a row.

About Agensys, Inc., an affiliate of Astellas Pharma Inc.:
Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in therapeutic antibody research and development in cancer. Agensys is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumour cancers. Agensys in January 2011 broke ground on a new 160,000-square-foot, state-of-the-art facility, which will help fulfill Astellas' mission of developing innovative pharmaceuticals for cancer patients with still unmet medical needs. In 2007, Astellas Pharma Inc. acquired Agensys with the plan to make it the center of the company's antibody product discovery and development operations.